is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, 𝗽𝗼𝗹𝗶𝗼𝗺𝘆𝗲𝗹𝗶𝘁𝗶𝘀 and invasive disease due to Haemophilus influenzae type b. Pentacel is approved for use as a four dose series in children 6 weeks through 4 years of age (prior to 5th birthday).

The following adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Pentacel.
• Cardiac disorders
• Cyanosis
• Gastrointestinal disorders
• Vomiting, diarrhea
• General disorders and administration site conditions
• Injection site reactions (including inflammation, mass, abscess and sterile abscess), extensive swelling of the injected limb (including swelling that involved adjacent joints), vaccination failure/therapeutic response decreased (invasive H. influenzae type b disease)
• Immune system disorders
•Anaphylaxis/anaphylactic reaction, hypersensitivity (such as rash and urticaria)
• Infections and infestations
• Meningitis, rhinitis, viral infection
• Metabolism and nutrition disorder
• If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré
syndrome may be increased following Pentacel.